This article is more than 5 years old. Information may no longer be current.
Topical and IV tranexamic acid use yielded decreased blood loss in THA
Click Here to Manage Email Alerts
Both topical and intravenous tranexamic acid decreased blood loss and reduced the need for transfusion among patients who underwent primary uncemented total hip arthroplasty, according to results.
Researchers randomly assigned 139 patients who underwent total hip arthroplasty (THA) to receive either tranexamic acid intravenously (n=70) or topically (n=69). Primary outcomes included assessment of blood and hemoglobin loss and transfusion rates within each group, while secondary outcomes included a transfusion cost analysis relative to historic controls and an assessment of thromboembolic events, according to researchers.
Results showed higher postoperative hemoglobin before discharge in the IV group vs. the topical group. The IV group also had significantly improved differences in lower postoperative hemoglobin and change in hemoglobin, according to results, as well as less calculated hemoglobin loss and calculated blood loss. Researchers found a 14% transfusion rate for all patients, with a lower rate of transfusion among patients in the IV group vs. the topical group.
Six patients, including two patients from the IV group and four patients from the topical group, experienced postoperative complications, researchers noted. Use of tranexamic acid revealed a savings of $314 per patient when researchers compared the findings with their historic transfusion rate. – by Casey Tingle
Disclosures: North reports no relevant financial disclosures. Please see the full study for a list of all other authors’ relevant financial disclosures.
Click Here to Manage Email Alerts